

RX 110 INC.

MANAGEMENT DISCUSSION AND ANALYSIS

The following discussion and analysis of the financial results for the interim period ended March 31, 2011 should be read in conjunction with the Company's unaudited interim statements and related notes contained in this report and audited financial statements for the year ended September 30, 2010.

RISK AND UNCERTAINTIES

Certain statements included in this discussion may constitute forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance of achievements of the Company, or industry results, to be materially different from any future results, performance and achievements expressed or implied by such forward-looking statements. Such factors include changes in government regulations, general economic conditions and business conditions, which among other things may affect demand for the Company's activities and the ability of the Company to implement its business strategy.

RESULTS OF OPERATIONS

The interim statements of operations indicate net loss of \$45,224 for the three months period ended March 31, 2011.

QUATERLY INFORMATION

Quarter ended	Total Revenue	Net income (Net Loss)	Income (Loss) per share
March 31, 2011	0	(45,224)	(0.00165)
December 31, 2010	0	(17,828)	(0.00065)
September 30, 2010	0	(481,873)	(0.02758)
June 30, 2010	0	(4,037)	(0.00023)
March 31, 2010	0	(2,599)	(0.00015)

RX 110 INC.

LIQUIDITY

RX 110 Inc.'s working capital stands at \$74,652 compared to \$4,562 in the beginning of period, comprised of cash, accounts receivable and prepaid expenses.

OFF BALANCE SHEET ARRANGEMENTS

The Company has no off balance sheet arrangements.

IMPORTANT TRANSACTIONS

On December 15, 2010, the Company announced that it had entered into an exclusive license agreement with Rx100 Inc. to manufacture, import, market and sell in Canada filler products for stopping mould at source (the "Rx Products").

Pursuant to the terms of the License Agreement, and as compensation for Rx100 Inc. entering into the License Agreement, the company issued to Rx Inc. 10,000,000 Class A shares in the capital of the company and granted an ongoing royalty equal to 3% of all the company's revenues generated from the sale of Rx100 Products. The term of the License Agreement continues until the expiration of the last of the Rx100 patents.

DISCLOSURE OF OUTSTANDING SHARE DATA

The Company can issue an unlimited number of Class A shares, voting and participating. As at the date hereof 27,470,003 shares were issued.

ADDITIONAL INFORMATION AND CONTINUOUS DISCLOSURE

This Management's Discussion and Analysis has been prepared as at May 27, 2010. Additional information on the Company is available through regular filings of press releases; financial statements and its annual information posted on SEDAR (www.sedar.com).